Key clinical point: With more than 1 y follow-up, KTE-X19 demonstrated a significant and durable clinical benefit, with a manageable safety profile.
Major finding: Investigator-assessed overall response rate was 86% with a clinical response rate of 57%.
Study details: Assessment of 20 patients with R/R MCL who received KTE-X19, an autologous anti-CD19 CAR T cell therapy.
Disclosures: The Zuma-2 study was funded by Kite, a Gilead Company. There were no author disclosures indicated.
Wang M et al. Biol Blood Marrow Transplant. 2020 26:S1-S7.